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ABSTRACT Cell-derived microparticles are small (0.1–1 μm) vesicles shed by most eukaryotic cells upon
activation or during apoptosis. Microparticles carry on their surface, and enclose within their cytoplasm,
molecules derived from the parental cell, including proteins, DNA, RNA, microRNA and phospholipids.
Microparticles are now considered functional units that represent a disseminated storage pool of bioactive
effectors and participate both in the maintenance of homeostasis and in the pathogenesis of diseases. The
mechanisms involved in microparticle generation include intracellular calcium mobilisation, cytoskeleton
rearrangement, kinase phosphorylation and activation of the nuclear factor-κB. The role of microparticles in
blood coagulation and inflammation, including airway inflammation, is well established in in vitro and animal
models. The role of microparticles in human pulmonary diseases, both as pathogenic determinants and
biomarkers, is being actively investigated. Microparticles of endothelial origin, suggestive of apoptosis, have
been demonstrated in the peripheral blood of patients with emphysema, lending support to the hypothesis that
endothelial dysfunction and apoptosis are involved in the pathogenesis of the disease and represent a link with
cardiovascular comorbidities. Microparticles also have potential roles in patients with asthma, diffuse
parenchymal lung disease, thromboembolism, lung cancer and pulmonary arterial hypertension.
@ERSpublications
Microparticles are potential biomarkers and targets for therapeutic interventions in respiratory
medicine http://ow.ly/ZTCp6
Introduction
Virtually all eukaryotic cells shed submicron vesicles constitutively, upon activation or during apoptosis.
While their existence has been known for a long time, these structures were initially considered laboratory
artefacts or, at most, cell debris devoid of physiological significance. Only relatively recently have
researchers begun to appreciate their potential roles in physiology and pathophysiology, and their
involvement in processes as diverse as, for example, blood coagulation, inflammation, intercellular
signalling and tumour cell growth. Cell-derived vesicles may vary in size, composition and mechanisms of
generation, and depending on these characteristics they are usually called exosomes, microparticles (or
ectosomes) and apoptotic bodies; however, their precise identification and characterisation has proven
difficult, and a shared nomenclature for the different types of vesicles is still lacking.
In this review we will first discuss some basic aspects of microparticle function and generation and then
describe the roles of these vesicles as potential mediators and biomarkers in respiratory diseases. While we
will try to focus on the structures usually referred to as microparticles, it is not possible to avoid that some
of the data presented here are in fact related to other types of vesicles.
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Differential characteristics of extracellular vesicles
Cell-derived vesicles can be defined as spherical particles enclosed by a phospholipid bilayer [1]. The
dimensions of these structures vary and represent one of the characteristics that distinguish the three types of
vesicles previously mentioned: exosomes typically range in size between 30 and 100 nm, microparticles range
between 100 and 1000 nm, while apoptotic bodies are larger, with diameters between 1 and 3 µm [2].
Exosomes are generated by inward budding of the membrane that leads to the generation of multivesicular
bodies; these structures then fuse with the cell membrane and are released as exosomes [3]. Apoptotic bodies
are generated upon cell shrinkage and apoptotic death [3]. Microparticles, which as previously stated represent
the focus of this review, are formed by the outward blebbing of the plasma membrane with subsequent release
after proteolytic cleavage of the cytoskeleton [4]. Figure 1a shows the mechanisms of formation of these three
types of vesicles, while figure 1b represents a more detailed schematic of microparticle generation.
Historical perspective: microparticles as “platelet dust”
In 1955, O’BRIEN [5] described “platelet-like activity” in normal human serum. 12 years later, WOLF [6]
came to similar conclusions, demonstrating the presence of “platelet dust” in plasma. These two reports
are probably the first ever to describe what we now call microparticles. To understand what O’BRIEN [5]
and WOLF [6] meant by the expressions “platelet-like activity” and “platelet dust”, we must refer to the
classical view of the coagulation cascade, a simplified version of which, limited to the so-called extrinsic
pathway, is depicted in figure 2. The coagulation cascade comprises a series of enzymatic reactions, each
activating a proenzyme that becomes able to activate the next. Eventually, the enzyme thrombin (also
known as FIIa) cleaves fibrinogen, generating fibrin that represents the insoluble matrix of the clot. It has
been known for decades that several steps of the cascade require negatively charged phospholipids for the
reaction to take place with the appropriate kinetics. Activated platelets have long been considered the main
source of such membranes due to their small size, and therefore high surface/volume ratio, and to the fact
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FIGURE 1 Schematic representations of a) the three types of extracellular vesicles and b) microparticle generation in more detail.
FIGURE 2 Simplified scheme of the “extrinsic”
pathway of blood coagulation. F: factor.
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that upon activation platelets externalise the negatively charged phospholipid, phosphatidylserine [7].
What O’BRIEN [5] and WOLF [6] described was the presence, in both serum and plasma, of structures able
to support the aforementioned reactions; these fluids, by definition cell-free environments, must therefore
contain negatively charged phospholipids that are not cell-associated. These considerations led to the
concept that negatively charged membrane fragments are released from platelets.
Vascular microparticles beyond platelet dust
Besides platelets, other vascular cells shed microparticles, including endothelial cells [8], leukocytes [9] and
erythrocytes [10]. As previously mentioned, these microparticles have a procoagulant potential due to the
presence of phosphatidylserine on their surface [11]. However, the presence of tissue factor (TF), the initiator
of the so-called extrinsic coagulation pathway (figure 2), on the surface of some microparticles adds to their
procoagulant potential [11]. Accordingly, numerous studies have demonstrated a role for microparticles of
different cell origin in blood coagulation and thrombosis, both in vitro and in vivo [12–16]. However, besides
TF, microparticles have the potential to carry on their surface, and to enclose within their cytoplasm, other
molecules derived from the parental cells, including proteins, DNA, RNA and microRNAs. Over the years, a
picture has emerged that indicates that microparticles represent functional units with the potential of
representing a disseminated storage pool of bioactive effectors, neither soluble nor cell-associated, that
participate both in the maintenance of homeostasis and in the pathogenesis of disease [17].
Mechanisms involved in microparticle formation
The mechanisms involved in microparticle formation have only partially been elucidated; however, two
distinct, well-characterised pathways have been identified, namely cell activation and apoptosis [18].
Microparticle shedding caused by activation starts within minutes after the addition of the relevant agonist
[19] and is characterised by an increase in cytosolic calcium concentration [20]. In contrast, in
apoptosis-dependent microparticle formation, dynamic membrane blebbing follows cell contraction and
DNA fragmentation, and its time-course is usually measured in hours [21]. Several studies have
demonstrated that inhibition of the increase in cytosolic calcium prevents microparticle formation.
CAMPBELL et al. [22] demonstrated that the release of microparticles by S49 mouse lymphoma cells induced
by ionomycin was inhibited by EGTA, a calcium chelator. We have shown that EGTA inhibits peroxisome
proliferator-activated receptor (PPAR)-γ-induced release of microparticles by human monocytes/
macrophages (HMMs) [23]. In a similar model, using cigarette smoke extract as a stimulus for
microparticle release, we also inhibited microparticle generation with the L-type calcium channel blocker
verapamil [24]. Finally, the demonstration that calmodulin inhibition prevents cigarette smoke
extract-induced microparticle generation indicates a role for this calcium-binding messenger protein [24].
Different key regulators of the cytoskeleton have been identified in microparticle generation. BURGER et al. [8]
demonstrated that Rho kinases are involved in endothelial cell-derived microparticle (EMP) formation, since
Rho kinase inhibition blocked angiotensin II-induced release of microparticles. Furthermore, increased Rho
kinase activity causes the release of circulating EMPs [25]. In addition, the small GTPase RhoA triggers a
specific signalling pathway essential for microparticle biogenesis in various human cancer cells [26].
Other groups have demonstrated the involvement of mitogen-activated protein kinases (MAPKs) in
microparticle generation. For example, activating autoantibodies to the angiotensin II receptor type 1
obtained from hypertensive patients promote EMP generation through the activation of p38 MAPK
signalling, and p38 inhibitors effectively block this phenomenon [27]. Two groups have independently
shown that the p38 pathway is involved in EMP generation upon stimulation with indoxyl sulphate [28]
and tumour necrosis factor (TNF)-α [29]. In macrophage-derived microparticles obtained after stimulation
with tobacco smoke extract, the production of microparticles relies on a series of dynamic, regulated steps
that include activation of the c-Jun N-terminal kinase ( JNK) and p38 MAPKs [30]. In the same model,
other researchers have demonstrated that tobacco smoke extract exposure causes activation of JNK, p38
and extracellular signal-regulated kinase (ERK) MAPKs, as well as apoptosis, a major mechanism for
microparticle generation, and that only the inhibition of ERK, but not p38 or JNK, significantly blunted
tobacco smoke extract-induced microparticle generation [31]. In addition, we have demonstrated the
involvement of the ERK pathway in the generation of microparticles by human monocytes stimulated with
PPAR-γ agonists [23].
Recently, various studies have investigated the involvement of nuclear factor (NF)-κB in microparticle
generation. JOHNSON et al. [32] studied the mechanisms involved in the release of neutrophil-derived
microparticles (NMPs) after TNF-α stimulation, proving that the inhibition of NF-κB abrogates NMP
generation induced by activation of both TNF-α receptors, TNF1 and TNF2. The same results were
obtained in different cells by LEE et al. [33], who demonstrated the role of NF-κB in the release of human
umbilical vein EMPs.
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Potential role of microparticles in airway inflammation
The recruitment of blood-borne leukocytes into the airways represents a critical step in inflammatory
reactions and requires the orchestrated action of cytokines, chemokines and cell–cell adhesion molecules
[34]. Microparticles contribute to the production of various pro-inflammatory mediators by lung cells,
thus becoming potential key factors in the airway inflammatory process. We have demonstrated that
HMMs stimulated with the calcium ionophore A23187 and histamine generate microparticles with a
pro-inflammatory potential for human lung cells. These microparticles, incubated with bronchial and
alveolar epithelial cells, upregulate interleukin (IL)-8, monocyte chemotactic protein-1 and intercellular
adhesion molecule-1 synthesis [35]. We investigated the mechanisms leading to increased transcription of
pro-inflammatory mediators induced by HMM-derived microparticles. First, we demonstrated that
HMM-derived microparticles cause the translocation of NF-κB into the nucleus [36]. We then showed
that PPAR-γ agonists, such as rosiglitazone and 15-deoxy-Δ12,14-prostaglandin-J2, inhibit the phenomenon
[36], in keeping with the postulated anti-inflammatory role of these molecules that have in fact been
proposed as potential therapeutic targets in lung diseases [37]. Microparticles with a similar
pro-inflammatory potential on lung epithelial cells are also generated by HMMs exposed to cigarette
smoke extract [24]. In addition, FOGLI et al. [38] demonstrated that HMM-derived microparticles induce a
pro-inflammatory phenotype in human bronchial smooth muscle cells and that montelukast, a cysteinyl
leukotriene receptor antagonist, reverses the phenomenon. In particular, montelukast prevented nuclear
translocation of NF-κB, blocked IL-8 and prostaglandin E2 release and restored salbutamol response in
microparticle-stimulated human bronchial smooth muscle cells [38]. Finally, another group has
demonstrated that human lymphoblastoma T-cell-derived microparticles induce the production of
inflammatory cytokines, including TNF-α, IL-6 and IL-8, in a dose- and time-dependent manner by
human bronchial cells [39].
Complementary experimental approaches involving animal models have provided many insights that
contribute to the understanding of the relationships between airway inflammation and microparticle
generation. PORRO et al. [40] demonstrated that microparticles isolated from the sputum of cystic fibrosis
patients are pro-inflammatory when injected into the murine lung, determine a strong neutrophilic
infiltrate in the parenchyma and at the perivascular/peribronchial level, and that, among the possible
mediators involved, lipopolysaccharide has a putative role in this phenomenon. In addition, exogenous
EMPs injected into C57BL/6 mice caused a significant rise in pulmonary capillary permeability both as a
primary and secondary injury [41].
Microparticles in human lung diseases
Microparticles have been investigated in several human lung diseases as possible pathogenic elements, prognostic
markers and therapeutic targets. The data reported in the following sections are summarised in table 1.
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is associated with several relevant comorbidities, possibly
linked together through systemic inflammation [65–67]; among such comorbidities, cardiovascular
diseases are probably the most significant, especially in prognostic terms [68–73]. It is of note that the
presence of cardiovascular abnormalities has been demonstrated in a significant proportion of patients
affected by COPD, even in the absence of clinically evident cardiac disease [74–76]. These close
associations might be mediated by both endothelial dysfunction and activation, indicating an active
pathogenic role played by endothelial cells [77, 78] as well as by lung vasculature damage and apoptosis.
The latter is particularly relevant in the pathogenesis of emphysema and attributed, at least in part, to
reduced function and/or levels of vascular endothelial growth factor [79–81].
Based on these theoretical considerations, the potential role of EMPs as possible pathogenic effectors and/
or prognostic markers in emphysema and COPD has been recently investigated. In a study by GORDON
et al. [42], plasma EMPs were measured in 92 subjects, divided into healthy nonsmokers, healthy smokers
with normal pulmonary function tests and normal diffusing capacity of the lung for carbon monoxide
(DLCO), and “early emphysema” patients with normal pulmonary function tests but reduced DLCO.
Smokers with reduced DLCO had significantly higher EMP levels than the other two groups, suggesting
that EMPs could represent a potential marker of early emphysema. As previously mentioned,
microparticles may originate either from cell activation or apoptosis. Using validated surface markers,
GORDON et al. [42] were able to differentiate activated (high CD62E+ to CD31+ ratio) from apoptotic (low
CD62E+ to CD31+ ratio) EMPs and to demonstrate a high percentage of apoptotic EMPs in early
emphysema. Furthermore, the presence of angiotensin-converting enzyme on the surface of most EMPs
indicates their pulmonary capillary origin. Taken together, these observations are consistent with the
previously mentioned hypothesis that emphysema develops from a vascular bed injury in the lung and
that EMPs represent a suitable tool to investigate these phenomena.
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THOMASHOW et al. [43] analysed EMPs from 104 COPD patients and 76 controls, and found a significant
increase in CD31+ EMP levels (identified as apoptotic microparticles) in mild COPD, whereas CD62E+
EMPs (identified as activated microparticles) were higher in severe COPD. Additionally, apoptotic EMP
levels were positively correlated with the percentage of emphysema, measured by computed tomography
scan, and negatively correlated with pulmonary microvasculature perfusion, as assessed by magnetic
resonance imaging. Again, these observations suggest that pulmonary endothelial apoptosis could
represent an early step in emphysema development.
TAKAHASHI et al. [44] found a significant increase in both apoptotic and activated (CD31+ and CD62E+,
respectively) EMPs during exacerbations compared with stable COPD. Although expression of
angiotensin-converting enzyme was not assessed in this study, since the large majority of EMPs did not
express von Willebrand factor (a marker of systemic vasculature not expressed by pulmonary capillaries), it
was concluded that during an exacerbation pulmonary capillaries were mostly affected, both in terms of
apoptosis and activation/inflammation. Furthermore, the study showed that elevated baseline levels of
CD62E+ EMPs, suggestive of a sustained endothelial activation, even in stable COPD patients could
predict a susceptibility to exacerbations, thus representing a possible prognostic marker. In a later study by
the same investigators, a significant correlation between baseline CD62E+ EMP levels and annual change
in forced expiratory volume in 1 s (FEV1) was found: higher EMP levels predicted a more relevant decline
in FEV1, suggesting that a persistent endothelial activation and inflammation could play a role in the
functional decline of COPD patients [45].
Thus, analysis of pulmonary endothelial cell activation and apoptosis through EMP evaluation is proving
instrumental in generating data that lend further support to the hypothesis that COPD is a disease with a
TABLE 1 Summary of the known roles of microparticles (MPs) in human lung diseases
Disease and MP type Medium Significance or hypothesised role References
COPD
EMPs Plasma Markers of emphysema: increased apoptotic (CD31+) MPs in early
emphysema and mild COPD
[42, 43]
Prognostic markers for exacerbation susceptibility: increased apoptotic
(CD31+) and activated (CD62E+) MPs during exacerbations; increased
activated MPs in stable COPD at higher risk for future exacerbations
[44]
Prognostic markers for functional decline over time: correlation of
number of activated (CD62E+) MPs and FEV1 decline
[45]
Asthma
PMPs Plasma Role in organising bronchial inflammation [46]
TF-bearing MPs BALF Promoting hypercoagulability during asthma exacerbations [47]
Diffuse parenchymal lung disease
PMPs and MMPs Plasma Markers of lung involvement in systemic sclerosis [48]
TF-bearing MPs BALF Markers of disease severity; promoting myofibroblast differentiation
and activity
[49]
ARDS/ALI
Total MPs BALF Local activation of the coagulation cascade; possible target for treatment [50]
LMPs Plasma Prognostic markers: increased in survivors [51]
Pulmonary embolism and VTE
EMPs Plasma Promoting clot formation? (inconclusive data) [15, 52]
TF-bearing MPs Plasma Promoting clotting in cancer patients [53–56]
Plasma Possible markers for therapeutic decisions (i.e. thromboprophylaxis) [57]
Lung cancer
PMPs and MMPs Plasma Promoting hypercoagulability and tumour angiogenesis [58]
Total MPs, PMPs and EMPs Plasma Prognostic markers? (inconclusive data); increased “activated” EMPs
(CD31+CD42b−annexinV−) in survivors
[59–61]
Pulmonary hypertension
TF-bearing MPs Plasma Prothrombotic role in advanced PAH [62]
EMPs Plasma Markers of endothelial damage [62]
Markers of different pathogenic patterns [63]
Prognostic markers [64]
COPD: chronic obstructive pulmonary disease; EMPs: endothelial cell-derived microparticles; FEV1: forced expiratory volume in 1 s; PMPs:
platelet-derived microparticles; TF: tissue factor; BALF: bronchoalveolar lavage fluid; MMPs: monocyte-derived microparticles; ARDS: acute
respiratory distress syndrome; ALI: acute lung injury; LMPs: leukocyte-derived microparticles; VTE: venous thromboembolism; PAH: pulmonary
arterial hypertension.
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significant endothelial component, which could link lung disease and its systemic (and especially
cardiovascular) comorbidities [78]. AGUSTÍ et al. [82] recently proposed a general model whereby the
lungs, endothelium, bone marrow and adipose tissue form a network, in which the lung represents an
external sensor, the endothelium an internal sensor and the bone marrow and adipose tissue the
responsive elements. The model, summarised in figure 3, is largely speculative and AGUSTÍ et al. [82]
acknowledged that much experimental work is needed in order to thoroughly identify the links between
the lungs and the other components. Microparticles may represent one such link. Notably, we have
reported that both leptin, an adipokine secreted by adipose tissue [83], and airborne pollutants [84] cause
microparticle generation in macrophages and endothelial cells.
Asthma
Asthma is usually characterised by different patterns of airway inflammation, with a complex network of
cellular and molecular mediators [85–87]. In contrast to COPD, very little is known about the possible role of
microparticles in asthma and the scarce available data are preliminary, so that further research in the field,
through properly designed studies, is needed. In a recent study conducted on 35 subjects (20 individuals with
asthma and 15 healthy controls), asthmatic patients showed significantly higher baseline levels of
platelet-derived microparticles (PMPs) than controls [46]. It is worth noting that all asthmatic patients were
taking inhaled steroids. This finding could mark a potential pathogenic role for PMPs in airways
inflammation, especially in organising cellular (in particular leukocyte) trafficking between blood and bronchi.
The interplay between inflammation and blood coagulation is well recognised; accordingly, an increased risk
of pulmonary embolism in asthmatics, with an association with exacerbations, has been described [88, 89].
MAJOOR et al. [47] investigated the role of viral infections in the haemostatic balance in asthmatic subjects.
They showed an increase in TF-bearing microparticles in the bronchoalveolar lavage fluid (BALF) of
asthmatics after experimental rhinovirus infection. They hypothesised that TF-bearing microparticles could
play a pathogenic role in the local activation of coagulation during asthma infectious exacerbations, although
the population sample was too small (14 individuals with asthma and 14 healthy controls) to allow for
definite conclusions.
Diffuse parenchymal lung diseases
Diffuse parenchymal lung diseases represent a very inhomogeneous group of pulmonary diseases [90],
with several different aetiologies and pathogenic patterns, most of them not clearly understood or, in fact,
even almost completely unknown. Moreover, many of these conditions are quite rare. Very few studies
have addressed the potential role of microparticles in diffuse parenchymal lung diseases. NOMURA et al.
[48] showed, in a small sample of 42 patients with progressive systemic sclerosis, that levels of PMPs and
monocyte-derived microparticles (MMPs) were increased compared with 30 healthy controls. More
interestingly, significantly higher levels of PMPs and MMPs were found in patients with pulmonary
involvement (i.e. with interstitial lung disease), compared with patients without lung disease. Such elevated
levels of microparticles might therefore represent a possible marker of more advanced disease and a
putative marker to stratify patients when choosing a treatment strategy, such as anti-platelet drugs.
A link between blood coagulation and pulmonary fibrosis is well recognised [91]. Based on the role of
microparticles in blood coagulation, we investigated their presence in diffuse parenchymal lung disease
patients [49]. We showed an increased number of microparticles in the BALF of 19 patients with
interstitial lung diseases compared with 11 control subjects. Furthermore, the microparticle-bound TF
(MP-TF) procoagulant activity was significantly higher in patients than in controls. When patients were
further divided into idiopathic pulmonary fibrosis (IPF) and non-IPF groups, the MP-TF procoagulant
activity was significantly higher in the former group. Additionally, a statistically significant negative
correlation was found between TF-bearing microparticles and both forced vital capacity and DLCO in IPF
patients [49]. In the same study, in vitro assays showed that an oxidative stimulus, namely H2O2, increased
the production of procoagulant microparticles by alveolar epithelial cells in culture [49]. Local synthesis of
FIGURE 3 Proposed interactions among the
environment, lungs, endothelium, bone
marrow and adipose tissue in the pathogenesis
of chronic obstructive pulmonary disease and
its comorbidities. Reproduced and modified
from [82] with permission.
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coagulation factor X and its activation to factor Xa in the lung has been implicated in the pathogenesis of
IPF. Factor Xa is a protease that, besides its well-known role in cleaving prothrombin to generate
thrombin, is also capable of cleaving the protease-activated receptor (PAR)-1 on fibroblasts, signalling
their differentiation into myofibroblasts and therefore potentially contributing to the fibrotic process [92].
Increased local synthesis of factor X and local expression of factor Xa has been demonstrated in IPF lungs
[92]. Our data are consistent with the existence of a pathway whereby an oxidative stress induces the
generation of procoagulant, TF-bearing microparticles that activate locally synthesised factor X to Xa, thus
inducing a PAR-1-mediated activation of fibroblasts and a profibrotic response.
Acute respiratory distress syndrome
In acute respiratory distress syndrome (ARDS) a burst of local inflammation is present, associated with an
activation of the coagulation cascade and a significant deposition of fibrin in the alveolar spaces. Based on
previous evidence of the activation of the TF pathway in ARDS [93], BASTARACHE et al. [50] found a
significantly higher concentration of microparticles in pulmonary oedema fluid from ARDS subjects than from
patients with cardiogenic pulmonary oedema. Moreover, microparticles from ARDS patients had a higher
procoagulant activity compared with those from patients with cardiogenic oedema. This procoagulant activity
was mainly due to the presence of increased concentration of TF in the fluid, which strongly correlated with
microparticle levels, indicating the presence of TF-bearing microparticles. As suggested by subsequent in vitro
analysis, the alveolar epithelium probably represented the main source of microparticles in ARDS.
Furthermore, the study showed a trend towards lower microparticle concentrations in ARDS patients who
survived compared with those who died of the disease. BASTARACHE et al. [50] speculated that microparticles
could play a key role in the activation of blood coagulation and in the deposition of fibrin in the alveolar
spaces that characterises ARDS, and that they might represent a potential target for future treatment of ARDS.
Apparently discordant results emerged from another study that analysed plasma and BALF levels of
microparticles of different cellular origin (leukocytes, neutrophils, endothelium and platelets) in 52
patients with ARDS and 22 controls [51]. Higher plasmatic levels of leukocyte-derived microparticles
(LMPs) were associated with a better prognosis in the ARDS group, a result apparently at odds with that
of BASTARACHE et al. [50]; in fact, these results only suggest that circulating LMPs, as opposed to PMPs and
MMPs, might be protective, possibly through their positive effects on vascular tone, as speculated in
previous works on sepsis and septic shock [94].
Finally, in a murine model, the injection of EMPs into mice induced a significant release of the
pro-inflammatory cytokines TNF-α and IL-1β, with a subsequent recruitment of neutrophils [95]. These
effects were further increased by the concomitant or sequential administration of bacterial
lipopolysaccharide, indicating that EMPs might represent a signal that primes the lung for the following
inflammatory response to an external injury. Again, from this point of view, EMPs could represent a
potential therapeutic target for ARDS. In conclusion, these studies have mainly hypothesised a role for
microparticles (especially for EMPs) in the pathogenesis of ARDS: in particular, EMPs could represent a link
between alveolar inflammation and coagulation (two key steps in the pathobiology of ARDS), and perhaps
even a target for future treatment.
Pulmonary embolism
The potential role of procoagulant microparticles in venous thromboembolism (VTE) has been extensively
investigated. A first series of studies measured the level of circulating microparticles, irrespective of their
MP-TF procoagulant activity. CHIRINOS et al. [15] found an increase in plasma levels of EMPs and of
EMP–monocyte conjugates in 25 patients with VTE compared with 25 healthy controls, suggesting that
during VTE episodes EMPs and their interactions with leukocytes could play a role in clot formation.
From this point of view, EMPs might represent a potential therapeutic target for preventing and treating
thromboembolic events.
In contrast, in another study, EMP and PMP levels were similar between patients with acute pulmonary
embolism and control subjects [52]. A difference in circulating EMP and PMP levels was found when the
pulmonary embolism group was compared with the control subjects without cardiovascular risk factors,
but disappeared when controls with cardiovascular risk factors were included [52], suggesting that
circulating microparticles simply represent markers of such cardiovascular risk factors.
A more recent study showed higher levels of total (i.e. irrespective of their cellular origin)
phosphatidylserine-positive circulating microparticles in 186 patients with VTE compared with 418
healthy controls [96]. Furthermore, there was a positive correlation between microparticle levels and risk
of a first VTE episode. Since the composition of microparticles gave biological plausibility to the
hypothesis of their prothrombotic properties, the study suggested a pathogenic role for circulating
microparticles in VTE events.
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While these reports did not investigate the possible functional role of MP-TF in clot formation, other
studies have mainly focused on in vitro tests for MP-TF procoagulant activity of circulating microparticles,
to better elucidate the pathophysiological relationship between microparticles and VTE. In a retrospective
study by GARCIA RODRIGUEZ et al. [97], the procoagulant activity of TF-bearing microparticles (MP-TF
activity) was higher in patients with suspected pulmonary embolism than in controls; however, there were
no significant differences between MP-TF activity in patients with confirmed pulmonary embolism and
patients without the disease. Since an exploratory analysis in the group with suspected pulmonary
embolism revealed higher levels of MP-TF activity in patients affected by cancer, GARCIA RODRIGUEZ et al.
[97] concluded that MP-TF activity was not part of the VTE event, but rather reflected the presence of
cancer. The prospective study by THALER et al. [98], conducted on patients with deep vein thrombosis
(with or without pulmonary embolism), came to similar conclusions and did not support the hypothesis
that TF-bearing microparticles play a clear role in the pathogenesis of thromboembolic events. In
conclusion, functional studies on MP-TF activity failed to definitively confirm the hypothesis that emerged
from previous studies that investigated the levels of circulating microparticles.
The association of VTE with cancer is well established [99] and the role of microparticles in this setting has
also been investigated. In a study by TESSELAAR et al. [53], in patients with VTE and metastatic cancer, MP-TF
activity was higher than in patients with cancer but no VTE, in healthy subjects or in patients with idiopathic
VTE. These findings suggest the possibility that tumour-derived microparticles might initiate the clotting
cascade in vivo in cancer patients, thus playing a pathogenic role. Similar results derive from other studies
that confirm that MP-TF activity is associated with cancer, with an “overactivity” in the presence of a VTE
event [54–56]. These findings support the hypothesis that these microparticles are produced by tumour cells,
play a pathogenic role in the development of VTE and may represent a potential biomarker for critical clinical
challenges such as, for example, the choice of the ideal prophylactic treatment in oncology patients. ZWICKER
et al. [57], in a phase II randomised trial, divided a cohort of 66 patients with a nonresectable cancer,
according to the levels of MP-TF activity (low and high levels); they further split the high-level group into two
arms, according to the administration of a prophylactic dose of enoxaparin. Patients with high levels of
MP-TF activity treated with enoxaparin showed a significantly lower cumulative incidence of VTE at
2 months compared with those not treated and with high levels of MP-TF activity, while the incidence was
similar to the low-level group, suggesting that levels of MP-TF activity could be used as a potential biomarker
to stratify the risk of VTE and drive the choice of a prophylactic anticoagulation strategy in cancer patients.
Lung cancer
Lung cancer represents the main cause of cancer death worldwide [100]. In order to reach an earlier
diagnosis and to better select patients for individual treatments, several biomarkers have been studied,
including microparticles, but with inconsistent results regarding the possible biological roles of
microparticles in lung cancer. In an early study by KANAZAWA et al. [58], PMP and MMP levels were
higher in 64 patients with lung cancer (both small and nonsmall cell lung cancer) compared with 30
controls. Additionally, in cancer patients, platelet activation markers were also higher than in controls,
suggesting a potential biological relationship between microparticles (both MMPs and PMPs) and vascular
complications (both hypercoagulability and tumour angiogenesis) in these subjects.
Other studies have confirmed the higher levels of different types of microparticles in patients with lung
cancer compared with healthy controls. These have mostly focused on the possible prognostic value of
microparticles in lung cancer but the results were discordant. FLEITAS et al. [59] found higher levels of total
circulating microparticles in 60 patients with nonsmall cell lung cancer compared with 60 controls, but the
most relevant finding was that, in cancer patients, higher baseline levels of microparticles were associated
with a better progression-free and overall survival. Discordant results emerged from another study
conducted in 107 end-stage nonsmall cell lung cancer patients, divided into 1-year survivors and
nonsurvivors, measuring PMPs and EMPs [60]. While there was no difference in PMPs and “apoptotic”
EMPs (defined as CD31+CD42b−annexinV+ microparticles) between the two groups, “activated” EMP levels
(defined as CD31+CD42b−annexinV− microparticles) were significantly higher in nonsurvivors [60]. After a
multivariate regression analysis, these higher levels were an independent predictor of 1-year mortality. This
result was clearly in contrast with the study by FLEITAS et al. [59]. Moreover, in a previous study on the topic
by the same investigators [61], both PMP and EMP levels were higher in 130 lung cancer patients compared
with 30 healthy controls, but they were not associated with the presence of metastasis or with cancer stage
(early versus advanced). All these data underline the need for further studies in this field, in order to better
elucidate the possible prognostic and therapeutic role of microparticles in lung cancer.
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a devastating disease, still characterised by a poor prognosis
despite treatment [101], with several recognised pathogenic mechanisms, including increased coagulability
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and thrombosis, and endothelial dysfunction [102–106]. Microparticles have been investigated in animal
models of PAH [107–109]. The results support the hypothesis that microparticles might act directly on
endothelial function by altering vascular balance, through a reduction of nitric oxide production, an
increase in oxidative stress and as a circulating source of vasoconstrictor agents such as thromboxane A2.
In human pulmonary hypertension, microparticles could represent both a pathogenic element and a
prognostic marker. A pathogenic role for microparticles in humans has been proposed in a study on 20
patients affected by PAH [62]. These subjects showed higher levels of endoglin+ EMPs compared with 23
controls. Moreover, patients had higher MP-TF activity than controls, with the highest values in more
severe hypertensive subjects (World Health Organization (WHO) functional classes III and IV and 6-min
walking distance <380 m). These data supported a theoretical relationship between endothelial damage and
PAH severity. Furthermore, the highest levels of TF-bearing microparticle activity in the most severe
subgroup of patients might underline the possible prothrombotic contribution of microparticles in the
advanced stage of disease. Finally, since endoglin is an accessory receptor for transforming growth
factor-β, involved in cell proliferation and in neoangiogenesis, EMPs could participate in the pathogenesis
of plexiform lesions and vascular remodelling.
Another study supported a role for microparticles in the pathogenesis of PAH [110]. In this study, 10
patients with idiopathic PAH showed a significant increase of CD39 nucleotidase expression and function
on microparticle membranes compared with 10 controls. Since CD39 has an ATP nucleotidase activity,
and since ATP has an endothelium-dependent vasodilatory effect on pulmonary arteries, the CD39
increased activity could contribute to further raise pulmonary vascular resistance by reducing ATP
endovascular concentration. Conversely, CD39 activity ultimately leads to a reduction in AMP
concentration, and since AMP is a potent stimulator for platelet aggregation and thrombosis, the increased
CD39 levels could also represent a compensatory mechanism in order to limit the pathogenic process.
Microparticles could also represent a marker of severity in pulmonary hypertension. AMABILE et al. [63]
found increased levels of EMPs in an inhomogeneous sample of 24 patients with pre-capillary pulmonary
hypertension, compared with 20 healthy controls. Although no relationships existed between EMPs and
disease severity as assessed by WHO functional classes or 6-min walking test, there were significant positive
correlations between haemodynamic parameters of disease severity and both CD144+ and CD31+ EMP
levels, and between CD62E+ EMP levels and systemic inflammation (evaluated with high-sensitivity
C-reactive protein). Taken together, these results may indicate that different types of EMP can represent
markers of different pathogenic pathways in pulmonary hypertension (with CD144+ and CD31+ EMP levels
as predictors of disease severity and CD62E+ EMP levels as markers of vascular inflammation), but also that
EMPs could represent potential markers to predict prognosis and to perhaps monitor response to
pharmacological treatments. In order to better elucidate these latter aspects, the same investigators analysed
the same cohort in a prospective study, with a 1-year follow-up [64], and found significantly higher
CD62E+ EMP levels in pulmonary hypertension patients who developed an adverse outcome (death or
worsening right heart failure) than in those with stable disease. Additionally, AMABILE et al. [64] identified a
cut-off value for CD62E+ EMP levels to independently predict a worse prognosis. These data suggest that
CD62E+ EMP levels could be used as a prognostic marker to better stratify pulmonary hypertension
patients before starting a specific treatment. Other studies demonstrated higher levels of circulating
microparticles in patients with pulmonary hypertension compared with healthy controls, but they did not
assess the potential utility of microparticles as prognostic markers in the clinical setting [111, 112].
Conclusive remarks and future directions
Microparticles are rapidly gaining consideration both as biomarkers and as potential targets for
therapeutic interventions. In the field of respiratory medicine, microparticles have, for example, the
potential to help identify COPD phenotypes and stratify disease severity, to improve risk stratification for
the development of VTE to better define prophylactic strategies, and to allow a better prognostic
characterisation of ARDS patients. Furthermore, as a pathogenic role for microparticles is clearly
emerging, the precise identification of the mechanisms involved in their formation is likely to prove
valuable in identifying much needed novel therapeutic targets.
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